Societe Generale Downgrades Bristol Myers to Hold Position Over Patent Expiries

Monday, 11 March 2024, 17:15

Societe Generale downgraded Bristol Myers Squibb (BMY) to a hold position, citing concerns over the drugmaker's pipeline's ability to counter upcoming patent expirations. The decision reflects a cautious outlook on Bristol Myers' future performance and strategic direction. Investors should monitor how the company addresses these challenges to maintain market competitiveness.

https://store.livarava.com/99bc4532-dfcb-11ee-9662-5254a2021b2b.jpe — Societe Generale Downgrades Bristol Myers to Hold Position Over Patent Expiries

Societe Generale Downgrades Bristol Myers to Hold Position

Societe Generale has lowered its rating on Bristol Myers Squibb (BMY) to hold, emphasizing the impact of impending patent expirations on the company's prospects.

Reason for the Downgrade

Concern over Pipeline: The downgrade stemmed from Societe Generale's belief that Bristol Myers' pipeline might not offset the adverse effects of upcoming patent expirations.

Investors are advised to carefully assess the implications of this decision on their investment strategies.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Societe Generale Downgrades Bristol Myers to Hold Position

Reason for the Downgrade

Related posts